Meridian Bioscience Inc (NASDAQ:VIVO) will pay $0.13 dividend on May 17, 2018

May 3, 2018 - By Mark Williams

Meridian Bioscience, Inc. (NASDAQ:VIVO) Corporate Logo
Big Money Sentiment decreased to 1.2 in Q4 2017. It has change of 0.17, from 2017Q3’s 1.37. The ratio dropped due to Meridian Bioscience, Inc. positioning: 21 sold and 44 reduced. 31 funds acquired positions and 47 increased positions. Investors holded 36.26 million in 2017Q3 but now own 36.52 million shares or 0.72% more.
National Bank & Trust Of Mellon invested in 0% or 793,855 shs. Robecosam Ag holds 0% or 4,734 shs. Gotham Asset Ltd Liability Corp owns 159,916 shs. Arizona State Retirement Systems holds 70,932 shs or 0.01% of its capital. Credit Suisse Ag has 148,443 shs. Alaska-based State Of Alaska Department Of Revenue has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Tower Rech Capital Lc (Trc) invested in 3,091 shs. Susquehanna Gru Limited Liability Partnership reported 52,361 shs. Prudential Public Limited Liability holds 0.04% or 923,400 shs. Assetmark stated it has 62 shs or 0% of all its holdings. Barrow Hanley Mewhinney & Strauss Ltd Company reported 0% stake. Tudor Investment Et Al has 46,042 shs for 0.02% of their capital. California State Teachers Retirement System reported 0% stake. Park National Oh reported 10,450 shs or 0.01% of all its holdings. Koch holds 0.03% or 14,412 shs.

Meridian Bioscience, Inc. had 0 sales and 2 buys since February 7, 2018. This’s net activity of $28,784. 1,000 shs valued at $14,034 were bought by McIlwraith John on Friday, February 23.

Shareholders expect $0.13 dividend by Meridian Bioscience Inc (NASDAQ:VIVO) to be distributed on May 17, 2018, according to Zacks. The dividend has May 4, 2018 ex-date. The dividend is 0.88 % based on Meridian Bioscience Inc’s price of $14.25. May 7, 2018 is the dividend’s record date and Apr 26, 2018 is the announcement date. VIVO is reaching $14.25 during the last trading session, after decreased 0.70%.Currently Meridian Bioscience, Inc. is uptrending after 7.87% change in last May 3, 2017. VIVO has also 150,589 shares volume. The stock underperformed the S&P 500 by 3.68%.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide.The firm is worth $602.89 million. The firm operates through Diagnostics and Life Science divisions.The P/E ratio is 27.94. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Ratings Coverage

In total 3 analysts cover Meridian Bioscience Inc (NASDAQ:VIVO). “Buy” rating has 0, “Sell” are 1, while 2 are “Hold”. 0 are bullish. With $16.0 highest and $11.0 lowest price target Meridian Bioscience Inc has $14.33 average price target or 0.56% above the current ($14.25) price. 3 are the (NASDAQ:VIVO)’s analyst reports since January 25, 2018 according to StockzIntelligence Inc. In Thursday, January 25 report Canaccord Genuity maintained it with “Hold” rating and $16.0 target. On Thursday, January 25 the stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Sell” rating given by Piper Jaffray. In Thursday, January 25 report Robert W. Baird maintained it with “Hold” rating and $16.0 target.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: